Durvalumab Shows Real-World Efficacy in Stage III NSCLC



A real-world UK study shows that durvalumab following chemoradiotherapy effectively extends overall and progression-free survival in patients with unresectable, stage III non-small cell lung cancer.
Medscape News UK



Source link : https://www.medscape.com/viewarticle/durvalumab-after-chemoradiotherapy-extends-survival-2025a1000s0f?src=rss

Author :

Publish date : 2025-10-20 12:00:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version